Loading...

APC anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_APC_083106
Con A-stimulated C57BL/6 mouse splenocytes (2 days) stained with H1.2F3 APC
  • H1dot2F3_APC_083106
    Con A-stimulated C57BL/6 mouse splenocytes (2 days) stained with H1.2F3 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
104513 25 µg 88 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104514 100 µg 275 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Stepanek O, et al. 2013. J Immunol. 190:1807. PubMed
  2. Kongsomboonvech AK, et al. 2020. PLoS Pathog. 16:e1008327. PubMed
  3. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  4. Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed
  5. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  6. Wang L, et al. 2022. Nutrients. 15: . PubMed
  7. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  8. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  9. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  10. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  11. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  12. Català C, et al. 2022. iScience. 25:105078. PubMed
  13. Files M, et al. 2022. NPJ Vaccines. 7:48. PubMed
  14. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  15. Diao L, et al. 2022. iScience. 25:105511. PubMed
  16. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  17. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  18. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  19. Wang Z, et al. 2021. J Immunother Cancer. 9: . PubMed
  20. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  21. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  22. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  23. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  24. Wang Z, et al. 2019. J Clin Invest. 130:4850. PubMed
  25. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  26. Woyciechowski S, Hofmann M, Pircher H 2017. Eur J Immunol. 47:244-250. PubMed
  27. Dolina JS, et al. 2020. Cell Rep. 107249:31. PubMed
  28. Qu J, et al. 2018. J Immunol Res. 2018:7519856. PubMed
  29. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  30. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  31. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  32. Hojo MA, et al. 2019. Nat Commun. 2.224305556. PubMed
  33. Lee J, et al. 2022. Clin Transl Med. 12:e1021. PubMed
  34. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  35. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  36. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  37. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  38. Xu L, et al. 2012. J Immunol. 188:248. PubMed
  39. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  40. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  41. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  42. Kim S, et al. 2021. Elife. 10:. PubMed
  43. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  44. Morrison V, et al. 2015. J Immunol. 195: 105 - 115. PubMed
  45. Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed
  46. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  47. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  48. Xie X, et al. 2009. J Immunol. 182:7163. PubMed
  49. Lebrun A, et al. 2015. J Immunol. 195: 4358 - 4368. PubMed
  50. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  51. Li J, et al. 2020. Development. :. PubMed
  52. Shissler SC, et al. 2020. Sci Rep. 10:8218. PubMed
  53. Okuma A, et al. 2021. Methods Mol Biol. 2312:3. PubMed
  54. Elliot TAE, et al. 2021. Immunity. 54:2481. PubMed
  55. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  56. Yan C, et al. 2022. NPJ Precis Oncol. 6:6. PubMed
  57. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  58. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  59. Hsia HC, et al. 2017. J Leukoc Biol. 101:1053. PubMed
  60. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  61. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  62. Lin Y, et al. 2012. Cancer Prev Res. 5:1090. PubMed
  63. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
RRID
AB_492843 (BioLegend Cat. No. 104513)
AB_492843 (BioLegend Cat. No. 104514)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account